Abstract
The protozoan parasites, Trypanosoma brucei and T. cruzi, that cause sleeping sickness in sub-Saharan Africa and Chagas Disease in Latin America, respectively, exert significant morbidity and mortality in man. Combinations of toxicity and differential efficacy of current drugs provide an urgent need to develop novel, cheap and effective chemotherapies. Research over the last decade with cultured trypanosomes and mice experimentally infected with these parasites has demonstrated that trypanosome cysteine proteinases are valid targets for the rational design of new drugs. In particular, potent peptidyl and peptidomimetic inhibitors of brucipain (a.k.a. trypanopain-Tb) and cruzain (a.k.a. cruzipain), the respective cysteine proteinases of T. brucei and T. cruzi, have proved trypanocidal. Efforts are ongoing to develop more specific non-toxic inhibitors of various chemistries with improved biological half-lives and biovailability characteristics. Here, the biochemical and biological properties together with the history, current status and perceived directions on the development of specific inhibitors of trypanosome cysteine proteinases will be reviewed.
Keywords: September 2000, Protozoan Parasites, Trypanosma brucei, Plasmodium, Leishmania, T conglense, Cathepsin, Cysteine proteinase Inhibitors
Current Drug Targets
Title: Cysteine Proteinases of Trypanosome Parasites Novel Targets for Chemotherapy
Volume: 1 Issue: 2
Author(s): C. R. Caffrey, S. Scory and D. Steverding
Affiliation:
Keywords: September 2000, Protozoan Parasites, Trypanosma brucei, Plasmodium, Leishmania, T conglense, Cathepsin, Cysteine proteinase Inhibitors
Abstract: The protozoan parasites, Trypanosoma brucei and T. cruzi, that cause sleeping sickness in sub-Saharan Africa and Chagas Disease in Latin America, respectively, exert significant morbidity and mortality in man. Combinations of toxicity and differential efficacy of current drugs provide an urgent need to develop novel, cheap and effective chemotherapies. Research over the last decade with cultured trypanosomes and mice experimentally infected with these parasites has demonstrated that trypanosome cysteine proteinases are valid targets for the rational design of new drugs. In particular, potent peptidyl and peptidomimetic inhibitors of brucipain (a.k.a. trypanopain-Tb) and cruzain (a.k.a. cruzipain), the respective cysteine proteinases of T. brucei and T. cruzi, have proved trypanocidal. Efforts are ongoing to develop more specific non-toxic inhibitors of various chemistries with improved biological half-lives and biovailability characteristics. Here, the biochemical and biological properties together with the history, current status and perceived directions on the development of specific inhibitors of trypanosome cysteine proteinases will be reviewed.
Export Options
About this article
Cite this article as:
Caffrey R. C., Scory S. and Steverding D., Cysteine Proteinases of Trypanosome Parasites Novel Targets for Chemotherapy, Current Drug Targets 2000; 1 (2) . https://dx.doi.org/10.2174/1389450003349290
DOI https://dx.doi.org/10.2174/1389450003349290 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Open Questions about Pulmonary Hypertension and Exercise Training: A Critical Review
Current Respiratory Medicine Reviews Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Repair: The Intricate Crosstalk between the Epicardium and the Myocardium
Current Stem Cell Research & Therapy Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Discovery of Anticoagulant Drugs: A Historical Perspective
Current Drug Discovery Technologies Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Syntheses of 2,3-Diarylated 2H-Benzo[e][1,2]Thiazine 1,1-Dioxides and their 3,4-Dihydro Derivatives, and Assessment of their Inhibitory Activity Against MCF-7 Breast Cancer Cells
Medicinal Chemistry Mitochondrially Targeted Antioxidants for the Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps)
Current Cardiology Reviews Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis
Current Nutrition & Food Science Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry